Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 4, 2005, Pages 244-250

  Lambert, Martin ^a   Conus, Philippe ^b   Naber, Dieter ^a   McGorry, Patrick D ^c   Schimmelmann, Benno Graf ^d  

^a UNIVERSITY OF HAMBURG   (Germany)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Atypical antipsychotics; First episode psychosis; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYNDROME; HOSPITAL ADMISSION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFUSAL TO PARTICIPATE; REMISSION; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 27844516056     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500500328418     Document Type: Article

References (19)

1. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2003;158:765-74.
2. McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis. J Clin Psychiatry 1999;60:794-5.
3. Montes JM, Ciudad A, Gascon J, et al. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:667-74.
4. Huguelet P, Girardet F. A Swiss retrospective naturalistic outcome study comparing risperidone and olanzapine in the treatment of schizophrenic insubjects. Schweiz Arch Neurol Psychiatr 2002;153:282-8.
5. Lambert M, Conus P, Schimmelmann B, et al. Comparison of Olanzapine and Risperidone in 367 first-episode patients with non-affective or affective psychosis. Pharmacopsychiatry, in press.
6. Godleski LS, Goldsmith LJ, Vieweg WV, et al. Switching from depot antipsychotic drugs to olanzapine in subjects with chronic schizophrenia. J Clin Psychiatry 2003;64:119-22.
7. Dossenbach MRK, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among subjects non-responsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62(Suppl 2):28-34.
8. Lambert M, Conus P, Lambert T, McGorry PD. Pharmacotherapy of first-episode schizophrenia. Expert Opin Pharmacother 2003;4:717-51.
9. McGorry PD, Killackey E, Lambert M, Elkins K, Lambert T. Summary Australian and New Zealand Clinical Practice Guidelines for the treatment of schizophrenia. Australasian Psychiatry 2003;11:1-13.
10. American Psychiatric Association.. Diagnostic Criteria from DSM-IV. Washington, DC: American Psychiatric Press; 1994.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. National Institute of Mental Health, Rockville, 1976.
12. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated subjects. Acta Psychiatr Scand 1987;334:1-100.
13. Kane JM, Leucht S, Carpenter D. Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12)
14. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9.
15. Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in subjects with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18-24.
16. Pantelis C, Lambert TJ. Managing patients with "treatment- resistant" schizophrenia. Med J Aust 2003;178:62-6.
17. Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD005237.
18. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 668 patients with first-episode psychosis. Acta Psychiatrica Scand 2005;112:141-8.
19. Schimmelmann BG, Conus P, Edwards J, McGorry PD, Lambert M. Diagnostic stability 18 months after a first diagnosis of psychosis. J Clin Psychiatry, in press.